Cardiometabolic disorders, including type 2 diabetes mellitus, obesity, and cardiovascular disease, represent significant global health issues. Incretin-based therapies, specifically Semaglutide, Liraglutide, and Tirzepatide, are utilized to manage hyperglycaemia and obesity, and have been investigated for their impact on cardiometabolic risk markers and certain cardiovascular and renal outcomes.
Key Clinical Findings
The studies evaluated the pharmacology of Semaglutide, Liraglutide, and Tirzepatide, differentiating between surrogate cardiometabolic risk markers such as glycaemic control, body weight, and lipid parameters, and confirmed clinical outcomes including major adverse cardiovascular events and renal endpoints. Recent data from trials like SUSTAIN, LEADER, and SURPASS/SURMOUNT, alongside meta-analyses and observational studies, were incorporated. Results indicated that all three agents improved HbA1c, weight, and cardiometabolic outcomes. Tirzepatide generally demonstrated greater reductions across clinical trials. Semaglutide and Liraglutide consistently improved BMI, lipid profile, and cardiovascular risk. Renal outcomes were favorable across the class, though results varied based on baseline characteristics and trial design.